Growth Metrics

NovoCure (NVCR) Net Cash Flow (2016 - 2026)

NovoCure's Net Cash Flow history spans 13 years, with the latest figure at -$5.9 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow rose 83.91% to -$5.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$32.1 million, a 90.2% increase, with the full-year FY2025 number at -$63.1 million, up 17.3% from a year prior.
  • Net Cash Flow hit -$5.9 million in Q1 2026 for NovoCure, up from -$241.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for NVCR hit a ceiling of $214.9 million in Q1 2024 and a floor of -$288.8 million in Q2 2024.
  • Historically, Net Cash Flow has averaged -$6.6 million across 5 years, with a median of -$5.9 million in 2026.
  • Biggest five-year swings in Net Cash Flow: surged 2435.48% in 2024 and later crashed 949.62% in 2025.
  • Tracing NVCR's Net Cash Flow over 5 years: stood at -$128.4 million in 2022, then surged by 166.89% to $85.9 million in 2023, then crashed by 126.76% to -$23.0 million in 2024, then crashed by 949.62% to -$241.2 million in 2025, then surged by 97.54% to -$5.9 million in 2026.
  • Business Quant data shows Net Cash Flow for NVCR at -$5.9 million in Q1 2026, -$241.2 million in Q4 2025, and $192.5 million in Q3 2025.